

ASX Release

SUDA GRANTED AFRICAN PATENT FOR ARTIMIST™ ANTI-MALARIAL SPRAY

PERTH, AUSTRALIA – 31 July 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that it has been granted a patent in Africa for its novel ArTiMist™ anti-malarial spray. The patent was issued by the African Regional Intellectual Property Organization (ARIPO), which is an intergovernmental organisation for cooperation among African states in intellectual property matters. ARIPO comprises 19 member states, including the major countries in malaria-endemic Sub-Saharan Africa.

The patent covers the pharmaceutical composition of ArTiMist™, the route of delivery, the device and methods for the treatment of uncomplicated and complicated malaria. The patent number is AP/P/2013/006,997 and it expires in 2026.

ArTiMist™ was developed with a child in mind, particularly a child living in a challenging environment where healthcare facilities are far away and in many circumstances not fully equipped to treat paediatric malaria. The Phase III trial in severe paediatric malaria was successfully completed in Sub-Saharan countries. The results overwhelmingly demonstrate the superiority of ArTiMist™ to intravenous quinine. SUDA is currently in dialogue with the Medicines for Malaria Venture, the World Health Organisation and philanthropic groups regarding expanding the opportunity for ArTiMist™ to include its use as an early interventional treatment for malaria in the pre-referral setting.

Mr Stephen J Carter, CEO commented: "This new ArTiMist™ patent further strengthens our intellectual property in key malaria-endemic countries in Africa. The claims in this patent are extremely broad and, hence, ensure our proprietary ownership of artemether delivered in an oro-mucosal spray for the treatment of malaria. We are delighted to add this patent to our ArTiMist™ estate as we advance our discussions with the pharmaceutical industry and other major stakeholders in the field of malaria."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® is marketed in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au

About ArTiMist™

ArTiMist™ was designed with a child in mind; a child living in a challenging environment where healthcare resources can be very scarce and time is of the essence. ArTiMist™ is the world's first sub-lingual spray for the treatment of *p. falciparum* paediatric malaria. The active pharmaceutical ingredient in ArTiMist™ is artemether, which is a widely used anti-malarial and is currently administered by infusion or orally in a tablet form. ArTiMist™ is administered sublingually or under the tongue and enters the bloodstream where the parasite lives, attacking at a far greater speed than conventional tablets and reducing the need for continued hospitalisation whilst presenting significant cost savings to governments and relief organisations. ArTiMist™ could be particularly valuable as a pre-referral treatment of sick children before they are transferred to hospitals for definitive management of severe or moderately severe malaria.